# Ascentage Pharma Group International American Depository Shares (AAPG) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $17.61, market value $1.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Ascentage Pharma Group International American Depository Shares reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.9×**. Each dollar of revenue is priced at 2.9×.
- **Price / book: 19.8×**. The shares trade at 19.8× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -73.0%** (5-yr avg -51.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 91.5%**. Ascentage Pharma Group International American Depository Shares keeps 91.5% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -208.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -216.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: -93.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -142.6%**. Return on all capital, debt included, is -142.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -31.4%**. Each dollar of assets produces -31.4% of profit.

## Growth
- **Revenue growth (1 yr): 327.3%**. Revenue grew 327.3% over the last year.

## Financial health
- **Debt to equity: 1.49**. Debt is 1.49 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 0.4×**. It would take 0.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: -22.2×**. Operating profit covers interest only -22.2×: fragile.
- **Current ratio: 1.79** (quick 1.77). Current assets cover the next year's liabilities 1.79 times.
- **Altman Z-score: 0.38**. A Z-score of 0.38 is in the distress zone, a signal to examine the balance sheet closely.

## Dividends
- **Dividend: none**. Ascentage Pharma Group International American Depository Shares does not currently pay a dividend, but it returned -139.6% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Ascentage Pharma Group International American Depository Shares; the consensus is strong_buy, with an average price target of $47.44 (+169% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -54.3%** (YTD -32.9%, 3-mo 2.4%). The shares are down 54.3% over twelve months including dividends.
- **From 52-week high: -57.0%** (8.5% above the low). Trading 57% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.19** (volatility 58%). Beta of 1.19 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AAPG · Page: https://foliofundamentals.com/stocks/aapg

Not investment advice.